Argos Therapeutics (ARGS) Files $86.25M IPO
Tweet
Share
E-mailGet Alerts ARGS Hot Sheet
Join SI Premium – FREE
Argos Therapeutics, Inc. (Nasdaq: ARGS), filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $86.25 million. Argos plans to list on the New York Stock Exchange under the ticker "ARGS."
The offering is being made through Lazard Capital Markets, Canaccord Genuity, Needham & Company, LLC, and BMO Capital Markets.
Argos is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis.
The offering is being made through Lazard Capital Markets, Canaccord Genuity, Needham & Company, LLC, and BMO Capital Markets.
Argos is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- B&R Technology Merger Corp. raises $325M in Nasdaq IPO
- Southern Cross Acquisition closes $115M IPO on Nasdaq
- Liberty Energy and PowerBridge form joint venture for West Texas data campus
Create E-mail Alert Related Categories
IPOsRelated Entities
Needham & Company, BMO Capital, LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
